```markdown
# Page 2

start_of_treatment: Yes  
start_date: 05/22/2024  

A. PATIENT INFORMATION  
first_name: Shakh  
last_name: Abdulla  
dob: 04/01/2001  
address: 425 Sherman Ave Apt D  
city: Nashville  
state: TN  
zip: 37995  
home_phone: 865-395-3958  
work_phone:  
cell_phone: 865-395-0481  
email:  
current_weight:  
weight_unit:  
height:  
height_unit:  
allergies: No known allergies  

B. INSURANCE INFORMATION  
member_id: LAJM14345116  
other_coverage: No  
group_number: 435000  
other_member_id:  
carrier_name: BC TENNCARE  
insured_name: Abdulla, Shakh  

C. PRESCRIBER INFORMATION  
first_name: Hao  
last_name: Gu  
credentials: M.D.  
address: 3320 Montgomery Dr  
city: Nashville  
state: TN  
zip: 37361  
phone: 615-562-4848  
fax: 615-562-4820  
state_license_number:  
npi: 1154611523  
dea_number:  
upin:  
provider_email:  
office_contact_name: Erfan Rostami, RN  
office_contact_phone: 615-343-1176  

D. DISPENSING PROVIDER / ADMINISTRATION INFORMATION  
place_of_administration: Outpatient Infusion Center  
dispensing_provider_name: Golden Gate Infusion Center  
dispensing_provider_phone: 614-295-7655  
dispensing_provider_fax: 614-225-3355  
dispensing_provider_address:  
dispensing_provider_city:  
dispensing_provider_state:  
dispensing_provider_zip:  
dispensing_provider_tin:  
dispensing_provider_pin:  
dispensing_provider_npi:  

E. PRODUCT INFORMATION  
product_requested: Truxima (rituximab-abbs)  
dose: 694 mg  
directions_for_use: IVPB infusion 694 mg once (loading dose day 1)  
hcpcs_code: J9312  

F. DIAGNOSIS INFORMATION  
primary_icd_code: G35  
other_icd_code:  

G. CLINICAL INFORMATION  
prior_therapy_with_requested_within_365_days: No  
trial_and_failure_of_rituximab_biosimilars: No  
date_of_trial_and_failure:  
nature_of_failure:  
adverse_reaction_to_rituximab_biosimilars: No  
date_of_adverse_reaction:  
nature_of_adverse_reaction:  
contraindication_to_preferred_biosimilars: None  

trial_and_failure_of_inflectra_renflexis_simponi_aria: No  
date_of_trial_and_failure_inflectra:  
nature_of_failure_inflectra:  
adverse_reaction_to_inflectra_family: No  
date_of_adverse_reaction_inflectra:  
nature_of_adverse_reaction_inflectra:  
contraindication_to_inflectra_family: None  

trial_and_failure_of_enbrel_humira_idacio_rinvoq_tocilizumab_tofacitinib: No  
date_of_trial_and_failure_tnfs:  
nature_of_failure_tnfs:  
adverse_reaction_to_tnfs: No  
date_of_adverse_reaction_tnfs:  
nature_of_adverse_reaction_tnfs:  
contraindication_to_tnfs: None  

rituximab_used_concomitant_with_other_biologic_dmards: No  

acute_lymphoid_leukemia: No  
autoimmune_hemolytic_anemia: No  
anca_associated_vasculitides: No  
autoimmune_blistering_diseases: No  
b_cell_lymphomas: No  
castlemans_disease: No  
cns_lymphomas: No  
cll_or_sll: No  
cryoglobulinemia: No  
graft_versus_host_disease: No  
hairy_cell_leukemia: No  
solid_organ_transplant: No  
immune_checkpoint_encephalitis: No  
idiopathic_thrombocytopenic_purpura: No  
kidney_transplant_rejection_prophylaxis: No  
lymphocyte_predominant_hodgkin: No  

multiple_sclerosis_rrms: Yes  
multiple_sclerosis_spms: No  
multiple_sclerosis_ppms: No  
multiple_sclerosis_prms: No  
ms_discontinued_other_medications: No  

myasthenia_gravis_musk: No  
neuromyelitis_optica: No  
opsoclonus_myoclonus_ataxia: No  

rheumatoid_arthritis: No  
sjogrens_syndrome: No  
tpp: No  
waldenstrom_macroglobulinemia: No  

continuation_request_samples: No  
length_of_time_on_rituximab:  
```